[Auto-inflammatory syndromes and pregnancy].
In familial mediterranean fever (FMF), fertility is normal in treated patients. There is no abnormality of spermatogenesis under usual therapeutic doses of colchicine. The risk of early abortion is increased if inflammatory attacks occur during the pregnancy. It is recommended to continue colchicine treatment during the conception and the pregnancy. Careful follow-up must be organized, even more in patients with renal amyloidosis. Breast-feeding is allowed under colchicine with no risk for the baby. There is no indication for systematic amniocentesis in FMF patients treated with colchicine.
Stankovic
Katia
K
Service de Médecine Interne, Centre de Référence des Amyloses d'Origine Inflammatoire et de la Fièvre Méditerranéenne Familiale, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Université Paris 6, Paris Cedex 20, France. katia.stankovic@tnn.aphp.fr
Hentgen
Véronique
V
Grateau
Gilles
G
D000022:Abortion, Spontaneous / Q000209:etiology; D001327:Autoimmune Diseases / Q000517:prevention & control*; D001942:Breast Feeding; D003078:Colchicine / Q000627:therapeutic use; D010505:Familial Mediterranean Fever / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D016742:Preconception Care; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control*; D011295:Prenatal Care; D013091:Spermatogenesis / Q000502:physiology; D050257:Tubulin Modulators / Q000627:therapeutic use
D050257:Tubulin Modulators; D003078:Colchicine